CFA
ALXN

Carroll Financial Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Carroll Financial Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7
Closed -$1K – 2024
2021
Q2 		$1K Buy
+7
New +$1.2K ﹤0.01% 1678
2019
Q2 		– Sell
-5
Closed – – 1769
2019
Q1 		$0 Buy
+5
New +$622 ﹤0.01% 1564
2015
Q2 		– Sell
-11
Closed -$2K – 1152
2015
Q1 		$2K Buy
+11
New +$1.99K ﹤0.01% 750

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Carroll Financial Associates's ALXN Position: Q3 2021 in Review

Carroll Financial Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 7 shares — an estimated $1K sold.

Carroll Financial Associates first reported a position in ALXN in Q1 2015 and held it in 3 quarters. The position peaked at $2K in Q1 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Carroll Financial Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Carroll Financial Associates sold 7 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1K.
  • Carroll Financial Associates first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Carroll Financial Associates's Alexion Pharmaceuticals position peaked at $2K in Q1 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Carroll Financial Associates's 13F filing for Q3 2021, filed 7 Oct 2021.